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Abstract
Direct and selective small molecule control of transcription factor activity is an appealing avenue
for elucidating the cell biology mediated by transcriptional programs. However, pharmacologic
tools to modulate transcription factor activity are scarce because transcription factors are not
readily amenable to small molecule-mediated regulation. Moreover, existing genetic approaches to
regulate transcription factors often lead to high non-physiologic levels of transcriptional activation
that significantly impair our ability to understand the functional implications of transcription
factor activity. Herein, we demonstrate that small molecule-mediated conformational control of
protein degradation is a generally applicable, chemical biological methodology to obtain small
molecule-regulated transcription factors that modulate transcriptional responses at physiologic
levels in human cells. Our establishment of this approach allows for the rapid development of
genetically-encoded, small molecule-regulated transcription factors to explore the biologic and
therapeutic impact of physiologic levels of transcription factor activity in cells.
Transcription factors are attractive targets for pharmacologic regulation because modulating
their activity provides a general method to alter physiology and pathology at the level of
gene regulation.1 The absence of prototypical ligand binding sites has encumbered the
discovery of small molecules that can selectively modulate transcription factor function.2
Since transcription factors employ much of their solvent-exposed surface to form large
multi-protein:DNA complexes, their activities could potentially be modulated by small
molecules that bind to those surfaces and induce or inhibit requisite protein:protein and
protein:DNA interactions. Small molecules that target such surfaces are difficult to develop
and, with few exceptions (such as nuclear hormone receptors), transcription factors have
proven to be intractable drug targets thus far.3–7
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Transcription factors are also difficult to regulate using genetic approaches. Transcription
factor activity can be controlled using tetracycline (tet)-inducible systems, but this approach
often results in high non-physiologic levels of transcription factor activity and substantial
basal levels of the tet-inducible protein.8 Furthermore, tet-inducible regulation requires the
incorporation of the tet-repressor in target cells and tissues. A small molecule-regulated
intein splicing strategy to activate the transcription factor Gli1 was recently reported, but
this approach requires substantial protein engineering to produce a transcription factor
inactivated by the intein insert and has a slow activation timescale (12–24 h).9,10 Other
strategies to regulate transcription factor activity are similarly challenged by non-
physiologic levels of activity and/or the requirement for significant engineering of the
transcription factor or target cell.11,12 The difficulties associated with activating
transcription factors at physiologic levels have significantly limited our ability to both
explore the consequences of dynamic regulation of transcription factor activity in normal
physiology and elucidate the therapeutic potential for transcription factor regulation to treat
human disease.
We recently showed that conformational control of protein degradation allows dose-
dependent control of the basic leucine zipper (bZIP) stress-responsive transcription factor
ATF6.13 In this approach, destabilized domains of mutant proteins (DDs) are fused to
transcription factors that are constitutively expressed in cells.14,15 The DD suppresses
transcription factor activity by targeting the entire fusion to proteasomal degradation. This
degradation can be dose-dependently inhibited by the addition of a small molecule DD
pharmacologic chaperone that binds to the poorly populated, folded DD conformation,
stabilizing and increasing intracellular concentrations of the entire fusion protein and thus
facilitating transcription factor activation. Here, we explore the potentially broad
applicability of this methodology to regulate the activity of transcription factors of multiple
structural classes within the physiologically relevant regime.
We initially tested the generality of our approach for transcription factor regulation by
fusing an FKBP12 DD14 to a constitutively active version of the winged-helix transcription
factor Heat-Shock Factor 1 (FKBP.cHSF1) (Figure 1A). HSF1 is a stress-responsive
transcription factor responsible for activating the cytosolic heat-shock response.16
FKBP.cHSF1 should be rapidly degraded in untreated cells, whereas the addition of
Shield-1, the FKBP12 small molecule pharmacologic chaperone, should stabilize
FKBP.cHSF1 (Figure 1A). Consistent with this prediction, we observe a robust, Shield-1-
dependent stabilization of FKBP.cHSF1 in nuclear fractions isolated from HEK293T-REx
cells expressing FKBP.cHSF1 (Figure 1B). Shield-1-dependent stabilization of
FKBP.cHSF1 results in a significant induction of the cHSF1 target genes Hsp90, Hsp70 and
Hsp40 (Figure 1C). Importantly, there is no induction of cHSF1 target genes in untreated
cells expressing FKBP.cHSF1. Shield-1 also does not induce expression of these genes in
cells transfected with our FKBP.YFP control plasmid, indicating that the increased
expression requires cHSF1 transcriptional activity (Figure 1B,C). The induction of cHSF1
target genes upon administration of Shield-1 is rapid, demonstrating significant upregulation
of Hsp70 mRNA levels in 3 h and reaching maximal induction in <16 h (Figure S1A).
Furthermore, Shield-1 activation of FKBP.cHSF1 allows dose-dependent control over both
the levels of the FKBP.cHSF1 protein and the cHSF1 transcriptional program at a range of
physiologically relevant levels (Figures 1D, S1B).
We next evaluated whether DD-transcription factor fusions could similarly be applied to
other structural classes of transcription factors. We fused a FKBP12 DD14 C-terminal to the
active, spliced XBP1s bZIP transcription factor (XBP1s.FKBP) – one of the transcription
factors activated in the canonical endoplasmic reticulum (ER) unfolded protein response
(UPR) (Figure 2A).17 The addition of Shield-1 to HEK293T-REx cells expressing
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XBP1s.FKBP stabilizes the entire fusion in nuclear fractions (Figure 2B). Shield-1-
dependent stabilization of XBP1s.FKBP increases expression of the XBP1s target gene
Erdj413 to levels consistent with those observed upon thapsigargin (Tg) treatment, which
activates the global, endogenous UPR (Figure 2C). Importantly, we observe no basal
induction of ERdj4 in untreated cells expressing XBP1s.FKBP. We also do not observe
increased expression of the UPR-induced gene Chop, which is not a target of XBP1s.13 Thus
Shield-1-dependent stabilization of XBP1s.FKBP increases ERdj4 expression selectively,
rather than through stress-dependent, global UPR activation. Furthermore, we observe a
Shield-1 dose-dependent increase in ERdj4 expression, demonstrating the capacity to
sensitively regulate the XBP1s transcriptional program at physiologically relevant levels
(Figure 2D). These results demonstrate that DDs can be applied to regulate the activity of
multiple structural classes of transcription factors in cells.
Inhibiting transcription factor activity is also of interest. We evaluated the potential for DD-
transcription factor fusions to inhibit transcriptional activity using a dominant negative
construct of the UPR-associated transcription factor ATF6 (ATF6(bZIP)) – a construct
prepared by removing the ATF6 trans-activation domain; Figure 3A).18 Stress-dependent
global UPR activation activates ATF6, which induces gene expression through
homodimerization and heterodimerization with XBP1s mediated through the ATF6 bZIP
domain.19 ATF6(bZIP) can dimerize with ATF6 or XBP1s and suppress stress-dependent
upregulation of UPR target genes induced by either transcription factor.
We prepared a fusion between a DD version of bacterial dihydrofolate reductase (DHFR)15
and ATF6(bZIP) (DHFR.ATF6(bZIP)). The DHFR DD is stabilized by the addition of the
DHFR pharmacologic chaperone trimethoprim (TMP), which should increase levels of
DHFR.ATF6(bZIP) and suppress stress-induced expression of XBP1s- and ATF6-selective
UPR target genes (e.g., Erdj4 and BiP, respectively13). HEK293T-REx cells expressing
DHFR.ATF6(bZIP) show no significant impairment in the expression of the UPR target
genes BiP and ERdj4 in the absence of TMP (Figure 3B). The addition of the UPR activator
tunicamycin (Tm) causes a similar induction of BiP in cells expressing DHFR.YFP or
DHFR.ATF6(bZIP), indicating that DHFR.ATF6(bZIP) expression in the absence of TMP
does not impair stress-dependent increases in UPR target gene expression. Pre-incubation of
cells expressing DHFR.ATF6(bZIP) with TMP sharply attenuates the Tm- or Tg-dependent
increase in BiP and ERdj4 expression, respectively, demonstrating efficient TMP-dependent
suppression of endogenous ATF6 and XBP1s activity. Furthermore, TMP dose-dependently
suppresses Tg-dependent BiP expression in cells expressing DHFR.ATF6(bZIP) (Figure
3C). Thus, these results demonstrate the capacity to sensitively suppress the activity of bZIP
transcription factors using the DD approach.
The ability of both DHFR- and FKBP- transcription factor fusions to regulate transcription
factor activity suggests that the DD approach could allow for the orthogonal, ligand-
dependent regulation of two transcription factors in a single cell. To test this prediction, we
transfected the previously reported, active DHFR.ATF613 into HEK293T-REx cells
expressing FKBP.cHSF1 and monitored the ligand-dependent induction of ATF6 and/or
cHSF1 target genes by qPCR (Figure 4A). In these cells, the addition of TMP (which
stabilizes DHFR.ATF6) induces expression of ATF6 target genes, but not cHSF1 target
genes (Figure 4B). Alternatively, the addition of Shield-1 (which stabilizes FKBP.cHSF1)
induces expression of cHSF1 target genes but not ATF6 target genes. The addition of
Shield-1 and TMP induces expression of both sets of genes. No effects on gene transcription
were observed in control HEK293T-REx cells expressing DHFR.YFP and YFP.FKBP (see
Figure S2). Thus, we can sensitively and orthogonally regulate the activity of two
transcription factors with small molecules in a single cell using the DD approach.
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Our results demonstrate that DD-dependent regulation of transcription factors is a generally
applicable strategy to develop and rapidly implement ligand-regulated transcription factors
of multiple structural classes in cells. Furthermore, we show that the regulation of
transcription factors using DDs allows for the dosable activation of transcriptional programs
to physiologically relevant levels and can be used to control multiple transcription factors in
a single cell. These DD-regulated transcription factors can be employed in any cell model
system of interest.13 This highly modular methodology for the DD-dependent regulation of
transcription factors provides a general experimental approach that can be applied to explore
the consequences of dynamically regulating transcription factor activity in normal
physiology and to test the possibility that modulating transcription factor activity can be
therapeutically beneficial to treat human disease. These objectives can now be accomplished
without the formidable challenges associated with extensive reengineering of transcription
factor sequences or identifying potent and selective small molecule modulators of a
transcription factor of interest. Currently, we are employing the DD-regulated transcription
factors described herein to explore the potential treatment of protein mis-folding and
aggregation diseases by activating stress-responsive transcription factors in disease models.
Our strategy likewise enables research into many other important biologic processes
dynamically regulated by diverse transcription factors, such as stem-cell differentiation and
development.
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Figure 1. Application of DDs to regulate the activity of the winged-helix transcription factor
HSF1
A) Model showing the Shield-1-dependent regulation of the FKBP.cHSF1 fusion protein.
The HSF1 sequence in this fusion protein lacks amino acids 186–202, which renders HSF1
constitutively active. The structure of Shield-1 is shown. B) Immunoblot of nuclear and
post-nuclear extracts of HEK293T-REx cells expressing FKBP.YFP or FKBP.cHSF1.
Shield-1 (1 μM) or vehicle was added to the indicated cells 18 h prior to harvest. C) qPCR
analysis of Hsp90, Hsp70, and Hsp40 in HEK293T-REx cells expressing FKBP.YFP or
FKBP.cHSF1. Shield-1 (1 μM) or vehicle was added 18 h prior to harvest, as indicated.
qPCR data are presented as fold-increase relative to vehicle-treated cells expressing
FKBP.YFP. D) qPCR analysis of Hsp70 in HEK293T-REx cells expressing FKBP.cHSF1
treated with increasing concentrations of Shield-1 for 18 h. qPCR data are presented as fold-
increase relative to vehicle-treated controls.
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Figure 2. Development and characterization of a small molecule-regulated XBP1s bZIP
transcription factor
A) Model showing the Shield-1 mediated stabilization of XBP1s.FKBP. B) Immunoblot of
nuclear and post-nuclear extracts isolated from HEK293T-REx cells expressing YFP.FKBP
or XBP1s.FKBP. C) qPCR analysis of ERdj4 and Chop in HEK293T-REx cells expressing
YFP.FKBP or XBP1s.FKBP. Shield-1 (1 μM) or vehicle was added for 18 h prior to harvest.
Cells treated with thapsigargin (Tg; 1 μM, 6 h) are shown as a control. qPCR results are
presented as fold-increase relative to vehicle-treated cells expressing YFP.FKBP. D) qPCR
analysis of Erdj4 in HEK293T-REx cells expressing XBP1s.FKBP and treated with
increasing doses of Shield-1 for 18 h. qPCR data are presented as fold-increase relative to
vehicle-treated controls.
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Figure 3. DD regulation of dominant negative ATF6
A) Domain architecture of dominant negative DHFR.ATF6(bZIP). B) qPCR of BiP and
ERdj4 in HEK293T-REx cells expressing DHFR.YFP or DHFR.ATF6(bZIP) pretreated for
15 h with TMP (10 μM) then challenged with either tunicamycin (Tm; 10 μg/mL; 6 h) or
thapsigargin (Tg, 10 μM, 6 h). C) qPCR of Bip in HEK293T-REx cells expressing
DHFR.ATF6(bZIP) pre-treated with increasing doses of TMP (15 h) then challenged with
Tg (10 μM, 6 h).
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Figure 4. Dual regulation of two DD-transcription factor fusions in a single cell
A) Illustration showing the incorporation of DHFR.ATF6 into HEK293T-REx cells
expressing FKBP.cHSF1. B) qPCR analyses of Grp94 and Hsp40 mRNA levels in cells
expressing FKBP.cHSF1 and DHFR.ATF6 treated with Shield-1 (1 μM), TMP (10 μM) or
both.
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